ReviewActa biomaterialia2014
Incorporation of heparin into biomaterials.
Review in Acta biomaterialia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 221 citations in OpenAlex.
- Phased affinity-controlled delivery of vascular endothelial growth factor, fibroblast growth factor-2, and platelet derived growth factor enhances in vitro angiogenesis.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Discovery and Characterization of Interleukin-4-Specific Affibodies for Affinity-Controlled Protein Release and Macrophage Polarization.bioRxiv : the preprint server for biology · 2026Article
- Heparin-Based Biomaterials for Sustained Release of Growth Factors for Bone Tissue Engineering and Regeneration.Journal of functional biomaterials · 2026Review
- Antithrombotic Polymers: A Narrative Review on Current and Future Strategies for Their Design, Synthesis, and Application.International journal of molecular sciences · 2026Review
- Sulfated Polysaccharides in Wound Healing: From Bioactive Materials Design to Regenerative Therapeutics.International journal of nanomedicine · 2026Review
- Engineering a heparin-mimetic biomaterial to promote tissue vascularization.Communications biology · 2025Article
- Functional Hydrogels: A Promising Platform for Biomedical and Environmental Applications.International journal of molecular sciences · 2025Review
- Heparin-Based Growth Factor Delivery Platforms: A Review.Pharmaceutics · 2025Review
- Delivery of Angiogenic Therapy from Flowable Hyaluronic Acid Porous Scaffolds Results in Functional Improvement without Anti-Inflammatory Agents.Advanced functional materials · 2025Article
- Applying Computational Protein Design to Engineer Affibodies for Affinity-controlled Delivery of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor.Biomacromolecules · 2025Article
- Hyaluronic acid as a versatile building block for the development of biofunctional hydrogels: In vitro models and preclinical innovations.Materials today. Bio · 2025Article
- Exploration of biomaterial-tissue integration in heterogeneous microporous annealed particle scaffolds in subcutaneous implants over 12 months.Acta biomaterialia · 2025Article
- Collagen-Heparin-FGF2-VEGF Scaffolds Induce a Regenerative Gene Expression Profile in a Fetal Sheep Wound Model.Tissue engineering and regenerative medicine · 2024Article
- Poly(lactide)-Based Materials Modified with Biomolecules: A Review.Materials (Basel, Switzerland) · 2024Review
- The role of extracellular matrix in angiogenesis: Beyond adhesion and structure.Biomaterials and biosystems · 2024Review
- Polysaccharide-Based Composite Systems in Bone Tissue Engineering: A Review.Materials (Basel, Switzerland) · 2024Review
- Development and Characterization of a Photocrosslinkable, Chitosan-Based, Nerve Growth Factor-Eluting Hydrogel for the Ocular Surface.Translational vision science & technology · 2024Article
- Biomimetic polymers with phosphorylcholine groups as biomaterials for medical devices.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2024Review
- A biomimetic approach to modulating the sustained release of fibroblast growth factor 2 from fibrin microthread scaffolds.Exploration of biomat-x · 2024Article
- Chemical and Biological Engineering Strategies to Make and Modify Next-Generation Hydrogel Biomaterials.Matter · 2023Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
This review provides an overview of the incorporation of heparin into biomaterials with a focus on drug delivery and the use of heparin-based biomaterials for self-assembly of polymer networks. Heparin conjugation to biomaterials was originally explored to reduce the thrombogenicity of materials in contact with blood. Many of the conjugation strategies that were developed for these applications are still popular today for other applications. More recently heparin has been conjugated to biomaterials for drug delivery applications. Many of the delivery approaches have taken advantage of the ability of heparin to bind to a wide variety of growth factors, protecting them from degradation and potentiating interactions with cell surface receptors. More recently, the use of heparin as a base polymer for scaffold fabrication has also been explored, often utilizing non-covalent binding of heparin with peptides or proteins to promote self-assembly of hydrogel networks. This review will highlight recent advances in each of these areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.